When samples from lung adenocarcinoma patients were selected for enrichment in CD8 cytotoxic T cells, the overall survival was 60 months (five years) in patients with the highest expression vs. 34 months in patients with the lowest expression (p = 0.0096; Figure 1D). Here, CD8A is linked to lung adenocarcinoma.